{
    "id": 1800,
    "name": "neuroendocrine carcinoma",
    "source": "DOID",
    "definition": "A carcinoma that derives_from neuroendocrine cells. [url:https\\://www.mayoclinic.org/diseases-conditions/neuroendocrine-tumors/symptoms-causes/syc-20354132]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:1800",
    "evidence": [
        {
            "id": 9876,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, treatment with DS-6051b was well-tolerated in patients with advanced solid tumors, and resulted in partial responses in two patients, including a patient with neuroendocrine carcinoma (Cancer Res July 15 2016 (76) (14 Supplement) CT024).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 1800,
                "name": "neuroendocrine carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7729,
                    "pubMedId": null,
                    "title": "Abstract CT024: First-in-human phase 1 dose-escalation study of DS-6051b, an oral ROS1 and NTRK inhibitor, in subjects with advanced solid tumors",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/CT024.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT03136055",
            "title": "Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5643,
                    "therapyName": "Irinotecan + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 4021,
                    "therapyName": "Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03190213",
            "title": "Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma (Pembro NEC)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03290079",
            "title": "Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03728361",
            "title": "Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3724,
                    "therapyName": "Nivolumab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04042714",
            "title": "TAS-102 in Extrapulmonary Neuroendocrine Carcinoma (TAS-102 NEC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2426,
                    "therapyName": "trifluridine/tipiracil hydrochloride",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04079712",
            "title": "Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2068,
                    "therapyName": "Cabozantinib + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        }
    ]
}